natgillin/translations-raw huggingface dataset:
A process for pickling a continuous strip of stainless steel comprising: treating the steel with a first mixture disposed in a first tub, the first mixture comprising H2SO4) an excess of at least one oxidizing agent, wherein the at least one oxidizing agent serves to convert a total amount of ferrous sulfate to ferric sulfate (Fe2(SO4)3), and applying a current to the steel, wherein the concentration of H2SO4 is from 10 g/L to 200 g/L. 
Postupak nagrizanja kontinuirane trake nehrđajućeg čelika, naznačen time što se sastoji u: obradi čelika prvom smjesom koja se nalazi u prvoj kadi, gdje prva smjesa sadrži H,SOx, najmanje jedan oksidans u suvišku, gdje najmanje jedan oksidans služi za prevođenje ukupne količine fero sulfata u feri sulfat (Fe(SO,)3), uz primjenu struje na čelik, gdje se koncentracija H,SOx kreće od 10 g/l do 200 g/l.
The liquefied gas treatment system according to any one of claims 1 to 10, wherein the engine includes an ME-GI engine and a DF engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što je glavni motor MEGI motor, a pomoćni motor je DF motor.
A composition according to any of claims 1 to 3, wherein the wt% ratio between the total amount of hygroscopic excipients and the total amount of benzodiazepines or salts thereof, calculated for the base, in the composition is from 20:1 to 1:1, preferably from 12:1 to 3:1, most preferably from 9: 1 to 3:1. 
Pripravak prema bilo kojem od zahtjeva 1 do 3, pri čemu je omjer mase % između ukupne količine higroskopnih ekscipijenasa 1 ukupne količine benzodiazepina ili njihovih soli, izračunat za bazu, u pripravku od 20:1 do 1:1, poželjno od 12:1 do 3:1, najpoželjnije od 9: 1 do 3:1.
The object is also achieved by a textile product containing the aforementioned hybrid yarn. 
Cilj je dakle dobivanje tekstilnog proizvoda koji sadržava gore navedenu hibridnu pređu.
Pharmaceutical composition according to any of the preceding items, wherein the dimethylfumarate is contained in a portion of the composition that provides for prolonged release of the active ingredient and one agent selected from teriflunomide, fingolimod and laquinimod is contained in a portion of the composition that provides for rapid release of the active ingredient. 
Kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time što je dimetilfumarat sadržan u dijelu pripravka koji osigurava produljeno oslobađanje djelatnog sastojka i jedno sredstvo odabrano između teriflunomida, fingolimoda i lakvinimoda je sadržano u dijelu pripravka koji osigurava brzo oslobađanje djelatnog sastojka.
The method of claim 2 wherein the modification is in a 5' untranslated region and or in a 3' untranslated region. 
Metoda iz patentnog zahtijeva 2 pri čemu je modifikacija u 5' netranslatiranom području 1 ili u 3' netranslatiranom području.
The compound of claim 6, wherein R43 and R44 are, independently, selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, and cyclopropyl. 
Spoj prema zahtjevu 19, pri čemu su R43 1 Ru nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil.
Figures 5a and 5b show in sectional views details of a fourth embodiment of a beverage dispensing assembly according to the invention. 
Slike 5a i 5b prikazuju pojedinosti presjeka četvrte izvedbe sklopa za točenje pića prema izumu.
The pharmaceutical composition of claim 7, wherein the VEGF antagonist is selected from the group consisting of an anti-VEGF antibody, a small molecule kinase inhibitor of VEGF receptor and a VEGF-inhibiting fusion protein. 
Farmaceutski pripravak prema zahtjevu 5 koji dalje sadrži antagonist VEGF-a, naznačen time, što je agonist VEGF-a opcionalno odabran iz anti-VEGF antitijela, kinaznog inhibitora malih molekula receptora VEGF-a i fuzijskog proteina koji inhibira VEGF.
A is an organic cation of the formula (R5R6N=CH-NR7R8)+, wherein: R5, R6, R7 and R8 are independently selected from hydrogen, unsubstituted or substituted C1-C20 alkyl, and unsubstituted or substituted aryl; B is a metal cation; 
(1ii) R7 je vodik, nesupstituirani ili supstituirani C,-C29-alkil, ili nesupstituirani ili supstituirani aril i (1V) Ra je vodik, nesupstituirani ili supstituirani Ci-C2o-alkil, ili nesupstituirani ili supstituirani aril; B je metalni kation odabran između Sn?* i Pb"*;
L is a leaving group, to form a compound of Formula VI. 
L je odlazeća skupina, da bi se dobio spoj čija je formula VI.
phenyl O a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof. 
Spoj naznačen time da se bira od [image] [image] njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov oblik N-oksida.
denotes hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, the hydrocarbon radicals of these groups being unsubstituted or substituted by one, two or three identical or different radicals Rc 
R* označava fenil, fenilkarbonil, fenilsulfonil, 5- ili 6-člani heteroaril, 5- ili 6-člani heteroarilkarbonil ili 5- ili 6-člani heteroarilsulfonil, pri čemu su sustavi prstena nesupstituirani ili supstituirani sa jednim, dva ili tri ista ili različita radikala R",
The method of claim 1, wherein each HPVLP is composed of more than 1, at least 5, 10, 20, 30, 40, 50, 60, 70 or 72 VP1 pentamers. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što HPVLP-i sadrže više od 1, najmanje 5, 10, 20, 30, 40, 50, 60, 70 ili 72 pentamera VP1.
planing equipment 63" 
oprema za ravnanje 63"
A computer readable recording medium having recorded thereon a program for executing the method of aspect 1 or aspect 7. A video decoding method using intra prediction, the video decoding method comprising: obtaining, from a bitstream, a most probable mode flag indicating whether one of candidate intra prediction modes is used to determine an intra prediction mode of a current block; 
PATENTNI ZAHTJEVI Postupak dekodiranja videa s korištenjem unutrašnjeg predviđanja, te postupak dekodiranja videa sadrži: - < dobivanje iz toka bitova, zastavice najvjerojatnijeg načina, koja označava da li je upotrijebljen jedan od kandidata načina unutrašnjeg predviđanja, za određivanje načina unutrašnjeg predviđanja trenutnoga bloka;
The receiving method according to claim 9, wherein the portion of bits are LSBs, Least Significant Bits, of the resource allocation information. 
Postupak prijenosa prema zahtjevu 9, naznačen time da su dio bitova potrebnih za označavanje dodijeljenog pluraliteta klastera LSB-ovi, Najmanje Bitni Bitovi, podatka o dodjeli resursa.
the proline at position 5 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of A, C, D, E, I, K, L, M, N, Q, R, S, T, V, or Y; 
prolin na položaju 5 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, I, K, L, M, N, Q, R, S, T, V i Y;
a bispecific antibody (Q499-z121/J327-z119/L404-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 20, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 25, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 32; 
25, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 32; bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 20, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 26, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 31; 1 nos
manual or mechanical stirring of said washing and separating container (1) for obtaining an emulsion of the fluid components, such as blood fluids, blood residues, oils and other solutions contained in the liposuctioned material allowing said fluids to remain separate from the solid cell material without the use of enzymes or chemicals, 
manualnog ili mehaničkog miješanja navedenog spremnika (1) za ispiranje i odvajanje radi dobivanja emulzije fluidnih komponenti, kao što su fluidi krvi, ostaci krvi, ulja i druge otopine koje su sadržane u materijalu koji je dobiven liposukcijom čime se omogućava navedenim tekućinama da ostanu odvojene od čvrstog staničnog materijala bez upotrebe enzima ili kemikalija, -
from 45% to 50% by weight on a dry weight basis of a pharmaceutically acceptable microcrystalline cellulose; 
ii) od 45 do 50 masenih postotaka na bazi suhe mase farmaceutski prihvatljive mikrokristalne celuloze;
Alkylation of amines of formula I may result in, but are not limited to, derivatives that include spacer units to other prodrug moieties such as substituted alkyoxymethyl-, acyloxymethyl-, phosphoryloxymethyl-, or sulfonyloxymethyl-groups. 
Alkilacija amina formule I može rezultirati u, ali bez ograničenja, derivatima koji uključuju slobodne jedinice za druge dijelove prolijekova kao što su supstituirani alkoksimetil-, aciloksimetil-, fosforiloksimetil-, ili sulfoniloksimetil- skupine, Alkilacija amina formule I može rezultirati u stvaranju kvaternih aminskih soli koje djelovanjem in vivo osiguravaju bioaktivni agens (npr., spoj formule
The excipients used in steps (ii) and (ii'), respectively, can be the same or different excipients as used in steps (i) and (i'), respectively. 
Ekscipijensi korišteni u koracima (ii) i (ii') mogu biti jednaki ili različiti ekscipijensima koji se koriste u koracima (i) i
The compound of claim 1, wherein the carbonyl and the Z group attached to ring A are disposed para to each other, or wherein the carbonyl and Z group attached to ring A are disposed meta to each other, or wherein the carbonyl and the Z group attached to ring A are disposed ortho to each other. 
Spoj prema patentnom zahtjevu 1, naznačen time što su karbonil i Z grupa vezani za prsten A postavljeni u para međusoban položaj ili time što su karbonil i Z grupa vezani za prsten A postavljeni u meta međusobni položaj ili time što su karbonil i Z grupa vezani za prsten A postavljeni u orto međusobni položaj.
Measurement of the lythic activity of CTL 
Datum objave europskog patenta:
The system of claim 15, wherein said electrolytic cell further comprises one or more electrolytic solution. 
Sustav u skladu s bilo kojim od patentnih zahtjeva 7 do 9, naznačen time, da navedena elektrolitička ćelija nadalje sadržava jednu ili više elektrolitičkih otopina.
The compound of Claim 34, wherein the compound is represented by the following structural formula: or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein: is CR54 or N; 
Spoj prema zahtjevu 34, pri čemu je spoj prikazan "dona strukturnom formulom: BEE ili njegov tautomer, farmaceutski oviyariiva sol, solvat ili klatrat, pri čemu: Xu] Je CRsa4 ili N;
g') choosing the internal reference bins IRB by an genetic algorithm from two candidate sets, the first candidate set being set of randomly selected bins, while bins corresponding to potentially aneuploid chromosomes are excluded, and the second candidate set being the set of bins corresponding to the best internal reference autosomes IRA determined in the previous step f'. 
2") odabir internih referentnih skupina polja (IRB) genetskim algoritmom iz dva kompleta kandidata, prvi komplet kandidata je komplet slučajno odabranih skupina polja, pri čemu se isključuju skupine polja koje odgovaraju potencijalnim kromosomima s aneuploidijom; i drugi komplet kandidata je komplet skupine polja koji odgovara najboljim internim referentnim autosomima IRA određenim u prethodnom koraku £f'.
Method according to claim 1 or 2, characterized in that the catalyst used in said reaction is a salt of an aliphatic sulphonic acid, preferably of methylsulphonic acid or of ethyl-sulphonic acid, or a salt of a fluorinated aliphatic sulfonic acid, preferably of trifluoromethane-sulfonic acid, pentafluoroethyl-sulfonic acid, or heptafluoropropyl-sulfonic acid. 
Postupak prema zahtjevu 1 ili 2, naznačen time da katalizator koji se koristi u navedenoj reakciji je sol metilsulfonske kiseline ili etilsulfonske kiseline, ili sol trifluorometan-sulfonske kiseline, pentafluoroetil-sulfonske kiseline, ili heptafluoropropil-sulfonske kiseline.
The pharmaceutical composition of any of emb 1-5, wherein the composition exhibits an in vitro dissolution profile such that after 2 hours, from about 0% to about 30% by weight of tapentadol is released, after 4 hours, from about 5% to about 22% by weight of tapentadol is released, after 6 hours, from about 15% to about 30% by weight of tapentadol is released, and after 8 hours, more than about 40% by weight of tapentadol is released; when measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37° C. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1-5, gdje pripravak pokazuje in vitro disolucijski profil takav da nakon 2 sata, otpušta se od oko 0% do oko 30% po masi tapentadola, nakon 4 sata, otpušta se od oko 5% do oko 22% po masi tapentadola, nakon 6 sati, otpušta se oko 15% do oko 30% po masi tapentadola, te nakon 8 sati se otpušta više od oko 40% po masi tapentadola; mjereno USP Basket postupkom pri 75 rpm u 900 mL 0.1 N HCI pri 37 *C.
the second fragment has a second proximal end; and wherein the first proximal end is within a short repeat and the second proximal end is within a short repeat; and wherein the first fragment and the second fragment are adjacent to one another and wherein the polypeptide elicits antibodies that neutralize toxin A and toxin B. 
drugi fragment ima drugi proksimalni kraj; i gdje prvi fragment i drugi fragment razdvaja manje od ili točno 5 aminokiselina u primarnoj strukturi, gdje polipeptid izaziva pojavu protutijela koja neutraliziraju i toksin A i toksin B, gdje je prvi proksimalni kraj unutar kratke ponavljajuće jedinice i drugi proksimalni kraj je unutar kratke ponavljajuće jedinice, gdje prvi proksimalni kraj i drugi proksimalni kraj ne prekidaju dijelove kratka ponavljajuća jedinica-duga ponavljajuća jedinica-kratka ponavljajuća jedinica.
wherein X and m are as defined above, with a compound represented by the formula (VIII): R1cCO2R8 (wherein R1c is as defined above; and R8 is alkyl), or 
O an gdje su X im kao što je definirano gore, sa spojem prema formuli (VIII): pri čemu je R'" definiran kao gore, a R* je alkil, ili 5
and pharmaceutically acceptable salts of compounds of Formula (I), and at least one pharmaceutically acceptable excipient; for use in a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one chemical entity. 
Barem jedan kemijski entitet i barem jedna farmaceutski prihvatljiva pomoćna tvar za upotrebu prema zahtjevu 7, gdje je spomenuta bolest, poremećaj ili medicinsko stanje poremećaj ciklusa budnosti 1 sna, insomnije, sindroma nemirnih nogu, "jet lag", smetnje pri spavanju i poremećaj spavanja sekundaran neurološkom poremećaju.
It is known to provide a cap to occlude he nozzle of an inhaler in order to prevent the entrance of dust and dirt. 
Poznato je da se na inhalator može postaviti zatvarač koji okružuje raspršivač inhalatora da se spriječi ulazak prašine i nečistoća.
The method according to paragraph 6, wherein the length of the data slice ID information is 8 bits. 
Metoda u skladu s patentnim zahtjevom 6, pri čemu duljina ID informacije podatkovnog reza iznosi 8 bitova.
A method of transmitting a broadcasting signal, the method comprising: 
Postupak odašiljanja emitiranog signala, postupak obuhvaća:
The effects of the isomers on spontaneous locomotor activity in rats were compared with the effects produced by tetrabenazine and haloperidol using the methods set out below. 
Učinci izomera na spontano lokomotorno djelovanje kod štakora su uspoređeni sa učincima tetrabenazina i haloperidola korištenjem dolje navedenih postupaka.
The CC50 (concentration that causes 50% growth inhibition) was calculated from the luminescence/concentration curve. 
CC50 (koncentracija koja uzrokuje 50% rasta inhibicije) izračunata je iz krivulje luminiscencija/koncentracija.
and R5 for each occurrence is, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; r is 0, 1 or 2; 
i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; r je 0, 1 ili 2;
The composition of claim 2 wherein said first agent binds to Smo. 
Sastav prema zahtjevu 2, naznačen time, da se spomenuto prvo sredstvo veže na Smo.
The dosage form of claim 1, comprising about 0.56 mg. of palonosetron hydrochloride and from about 100 to about 500 mg, or from about 200 to about 400 mg, or about 300 mg of netupitant or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak prema patentnim zahtjevima 1-2, naznačen time što navedena terapeutski efikasna količina netupitanta sadrži od oko 200 do oko 400 mg netupitanta ili njegove farmaceutski prihvatljive soli.
activating the oocyte comprises incubating the oocyte in the presence of thimerosal. Progeny of a genetically modified swine produced by the method of any one of claims 6, 7, 8, and 9, wherein in said progeny at least one allele of a SIGLEC1 gene is inactivated; at least one allele of a CD163 gene is inactivated; at least one allele of a SIGLEC1 gene and at least one allele of a CD163 gene are inactivated; or both alleles of a SIGLEC1 gene and both alleles of a CD163 gene are inactivated. 
Potomstvo genetički modificirane svinje uzgojene prema metodama iz bilo kojeg zahtjeva 6, 7, 8 i 9, pri čemu je u navedenom potomstvu barem jedna alela SIGLEC1 gena deaktivirana; barem jedna alela CD163 gena deaktivirana; barem jedna alela SIGLEC1 gena deaktivirana i barem jedna alela CD163 gena deaktivirana; ili su obje alele SIGLEC1 gena i obje alele CD163 gena deaktivirane.
The wine decanter device of one or more of the precedings claims 2 to 3 wherein said cup-shaped receptacle (5) is supported on the point of said conveyor (7). 
Uređaj za pretakanje vina iz jednog ili više prethodnih patentnih zahtjeva 2 do 3, pri čemu spomenuta posuda (5) u obliku šalice je oslonjena u točki spomenutog transportera (7).
25.The oral composition of any one of items 1 to 24, wherein the composition is lyophilized, heat dried, spray dried or freeze-dried. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu je sastav hiofiliziran, sušen toplinom, raspršen, pripremljen mokar ili brzo smrznut u otopini krioprotektanta.
A fibre moulded package (1) according to a preceding claim, wherein the window section extends along almost the entire length of the cover part, and wherein in an embodiment the window section is arranged with the cover part top surface in such a manner that a row of the plurality of accommodations (3) for receiving an egg is visible from the exterior of the package, and wherein in an embodiment the window section is arranged offset the centre of the package such that all of the number of window openings are oriented towards the centre of the package. 
Pakiranje oblikovano vlaknima (1) sukladno prethodnom zahtjevu, pri čemu se prozorski dio pruža duž gotovo čitave duljine pokrovnog dijela, i pri čemu je u dijelu prozora organiziran dio koji djeluje s pokrovnom površinom na način da nastaje niz od više smještajnih jedinica (3) za prihvat jaja koje su vidljive izvana, i pri čemu je u otvor prozorskog dijela organiziran izvan sredine pakiranja na način da du svi prozorski otvori orijentirani prema sredini pakiranja
The method of Claim 1 or Claim 2, wherein the 5' and/or the 3' end of the first CRISPR spacer of said CRISPR locus of said parent bacterial strain is compared with said modified CRISPR locus of said bacteriophage resistant variant strain. 
Postupak prema zahtjevu 1, naznačen time da se 5' i/ili 3' završetak barem prve CRISPR razmaknice navedenog CRISPR lokusa navedenog matičnog bakterijskog soja uspoređuje s navedenim modificiranim CRISPR lokusom navedenih varijanti sojeva rezistentnih na bakteriofag.
Use of claim 25 or claim 26, wherein the dermal pathologies are psoriasis, atopic dermatitis, chronic eczema, acne, pitiriasis rubra pilaris, keloids, hypertrophic scars and skin tumors. 
Uporaba prema patentnom zahtjevu 25 ili patentnom zahtjevu 26, naznačena time što, dermalne patologije su psorijaza, atopijski dermatitis, kronični ekcem, akne, pitirijazis rubra pilaris, keloidi, hipertrofirajuči ožiljci i tumori kože.
fixing the surround to the counter-frame in such a way as to form a single block, 
fiksiranje okruženja (12) na protuokvir (10) na takav način da se formira jedinični blok (12).
An anti-hPG monoclonal antibody that specifically binds a C-terminal region of human progastrin (hPG), which comprises the following VH and VL CDRs: 
Anti-hPG monoklonalno antitijelo koje se specifično veže za C-terminalnu regiju humanog progastrina (hPG), koje sadrži sljedeće Vu i Vr, CDRs:
The drive system according to claim 1 wherein said accumulator unit is charged with electrical energy recuperated from said drive motor when the drive motor is actuated such that its rotational speed is reduced in said controlled manner. 
Pogonski 1 upravljački sustav prema zahtjevu 1, naznačen time, da je navedena jedinica akumulatora napunjena električnom energijom koja je pojačana navedenim pogonskim motorom tijekom rada generatorskog modula.
Wind system (1) according to claim 7, characterised in that said permanent magnets are neodymium iron boron magnets. 
Vjetreni sustav (1) prema zahtjevu 1, naznačen time da je spomenuti sustav za vraćanje zmajeva (8) napravljen od jedne konstrukcije rešetkastog tipa.
Arrangement according to claim 5,characterized in that it further comprises a control arrangement for controlling the system when operating in liquid fuel and gaseous fuel modes, respectively, a controller (14) for controlling the pump (4) of gaseous fuel in liquid state when operating in gaseous fuel mode, a fuel controller (10) for controlling the system when operating in liquid fuel and gaseous fuel modes, respectively. 
Ustrojstvo u skladu sa zahtjevom 5, naznačeno time da nadalje sadrži upravljački uređaj za upravljanje sustavom tijekom rada u načinima rada tekućeg goriva i plinovitog goriva, odnosno, kontrolor (14) za upravljanje pumpom (4) plmovitog goriva u tekućoj fazi tijekom rada u načinu rada plinovitog goriva, kontrolor goriva (10) za upravljanje sustavom tijekom rada u načinima rada tekućeg goriva i plinovitog goriva, odnosno.
3 is a section of the lid of the hive from point C to D in the middle of the internal opening of FIG. 
Slika 3 prikazuje presjek poklopca košnice od točke C do D u sredini unutarnjeg otvora.
The method of claim 1, further comprising preparing the A ring reactant used in the third step of Scheme 1 by condensation of an a-aminophenylacetonitrile hydrochloride and oxazole-2-carbaldehyde in the presence of sulfur and TEA according to Scheme 4: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se 2-(oksazol-2-il)-4-feniltiazol-5-amin, koji služi kao međuprodukt u dobivanju spoja formule (I), dobiva kondensaziranjem a-aminofenilacetonitril-hidroklorida s oksazol-2-karbaldehidom, u prisutnosti sumpora i TEA.